The Peptide Boom That Matters Isn’t on Social Media. It’s a Psoriasis Pill Taking Aim at a Nearly $18 Billion Shot

Peptides have had a moment online — influencers injecting them for muscle and recovery — and compounding pharmacies may soon get the FDA’s leave to sell them. David Wainer’s Heard on the Street column says the peptide boom worth an investor’s attention is somewhere else, at a small biotech few influencers could name. Protagonist Therapeutics (PTGX) solved a problem that long stumped drugmakers — a peptide falls apart in the gut, so it comes as a shot — by building one that survives as a pill, and the psoriasis pill it developed with Johnson & Johnson (JNJ) is doing well enough that AbbVie (ABBV) shareholders have noticed.

A peptide is a short chain of amino acids: insulin is one, and so is the GLP-1 mimic inside Ozempic. Swallow one and the gut breaks it down like any protein, so peptides came as shots. The chemistry took Protagonist more than ten years, and the model was venom: snake and snail venom peptides are rings, not chains, so the gut finds no end to start on; CEO Dinesh Patel says the trick was copying that ruggedness without the poison. The result is Icotyde, launched earlier this year and heading for blockbuster sales: psoriasis patients have had pills for decades, but this is the first whose efficacy approaches that of the injected biologics. Within a few years, analysts expect it to sell more than $5 billion a year.

What the dermatologists are doing

Dermatologists surveyed by Bernstein’s Courtney Breen this summer had cut back sharply on the older pills — and were writing roughly a quarter fewer scripts for AbbVie’s Skyrizi, an injectable that sold nearly $18 billion last year. Nobody’s being switched off Skyrizi, Breen notes; a patient happy with a quarterly shot has little reason to take a daily pill. The threat is to Skyrizi’s growth: patients used to start on a weak pill, fail, then get a shot; now the first pill can work. Protagonist’s shares, helped by the pill, have more than doubled in a year; the company is now worth just under $9 billion.

Most of Icotyde’s money goes to J&J, though: Protagonist’s share is a royalty stepping from 6% to 10% of global sales, plus milestones if targets are hit, so BMO’s Evan Seigerman argues the stock is increasingly a bet on the platform — what that royalty cash can fund in wholly owned autoimmune and obesity programs. A second drug, Mimrylo, an injectable for a rare blood cancer partnered with Takeda (TAK), won FDA approval last month. Competition is arriving too, from Novo Nordisk’s (NVO) Wegovy pill, Merck’s (MRK) Lipfendra and a Novo deal worth up to $1.4 billion with Orbis Medicines.

Our read

There’s an investing lesson and a planning lesson. The investing lesson is about what a royalty is worth (IN04): a 6%-to-10% slice of a drug analysts see topping $5 billion a year is contracted cash, a rare thing in biotech, but at just under $9 billion of market value the stock’s case, as Seigerman says, rests increasingly on the platform, and the wholly owned pipeline is where the binary trial risk lives. The desk hasn’t added here; a single-stock biotech story is a watch, not a reserve buy. “The investment opportunity is something more durable,” Wainer writes, and durable is the word to hold him to.

The planning lesson is cheaper. Peptide injections of questionable provenance are a consumer-protection question (M11), not a wellness one; the approved pills are the ones with data. And for households budgeting a chronic condition into retirement, a pill with efficacy approaching the shots is a new option where injectables have ruled; whether it changes what you pay is worth a question at the next plan review, right after the statement.